SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Aeolus Pharmaceuticals (AOLS)

AOLS RSS Feed
Add AOLS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Sheep
Search This Board: 
Last Post: 7/24/2017 3:51:38 PM - Followers: 16 - Board type: Free - Posts Today: 0

NASDAQ BB

http://www.aolsrx.com/

Strategy

Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance.  We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology. We are currently doing this with AEOL 10150, where we are leveraging the potential substantial government investment in research and development of AEOL 10150 as a medical countermeasure to develop the compound in oncology indications, where it would be used in combination with radiation therapy

Business Overview

 We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase ("SOD").  While the benefits of antioxidants in reducing oxidative stress are well-known, research with our compounds indicates that metalloporphyrins can be used to affect signaling via ROS at the cellular level.  In addition, there is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation.

Our lead compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.  We are leveraging the significant investment made by U.S. government agencies to develop this promising compound for use in oncology indications, where it would be used in combination with radiation therapy, and is currently in development for use as both a therapeutic and prophylactic drug. 

AEOL 10150 has previously been tested in two Phase I clinical trials with no serious adverse events reported.  Data have already been published showing that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.  Early next year we expect to release data showing the drug's impact, if any, when used in combination with radiation and/or chemotherapy.  In mid-2011 we expect to begin Phase I/II studies in non-small cell lung cancer ("NSCLC").

AEOL 10150 is also being developed as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome ("Pulmonary Acute Radiation Syndrome" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome ("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event.  It is also being developed for use as a countermeasure for exposure to chemical vesicants such as chlorine gas and sulfur mustard gas.  AEOL 10150 has already performed well in animal efficacy and safety studies in each of these potential indications.  A significant portion of the funding for the medical countermeasure development programs to date has come from various government entities.    Although our management expects this funding to continue, there is no guarantee that it will do so.  We have submitted proposals to the Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as countermeasures for both Lung-ARS and cholorine gas exposure.  We are awaiting a final decision from BARDA on the contract.  If the contract from BARDA is awarded, it is expected that it will fund all of the costs to bring AEOL 10150 to FDA approval for that indication.

We have two programs underway for the development of our second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson's disease.   These programs are being funded, in part, by private foundations and government grants.

 

 PDF Presentation Feb 2011:  www.aeoluspharma.com/wp-content/uploads/2010/10/Aeolus-Presentation-January-2011_Web.pdf

 

 

Share Structure:

60,470,718 outstanding shares as of  MAY 10,2011
200,000,000 shares authorized

~ 6 - 9 Million shares in the Float
as of Jan 26, 2011

 

 

Point of Contact:

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
(949)481-9825, (949)481-9829 fax

















AOLS (Daily)


AOLS (Weekly)








 

AOLS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AOLS News: Quarterly Report (10-q) 05/15/2017 05:59:03 PM
AOLS News: Current Report Filing (8-k) 03/24/2017 11:51:26 AM
AOLS News: Quarterly Report (10-q) 02/17/2017 04:04:16 PM
AOLS News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 02/14/2017 11:17:47 AM
AOLS News: Amended Annual Report (10-k/a) 01/30/2017 05:06:26 PM
PostSubject
#461   The BARDA Lung ARS contract, awarded in 2011, jimbob4stocks 07/24/17 03:51:38 PM
#460   It's almost August! 60 days is coming jimbob4stocks 07/24/17 08:52:05 AM
#459   I am still holding and adding small chunks Sheep 07/21/17 01:08:03 PM
#458   Look at the AEZS chart and after FDA jimbob4stocks 07/20/17 08:31:43 AM
#457   10 4 sounds great let's hope we get MADDSTACKER 07/19/17 04:49:20 PM
#456   https://www.fda.gov/ForPatients/Approvals/Fast/ucm405399.htm Fast Track desig jimbob4stocks 07/19/17 04:42:12 PM
#455   I read that , I don't see where MADDSTACKER 07/19/17 04:40:41 PM
#454   http://www.marketwired.com/press-release/aeolus-announces-fda-fast-track-designa jimbob4stocks 07/19/17 04:39:58 PM
#453   I see February they started trial 1 , MADDSTACKER 07/19/17 04:38:03 PM
#452   I don't see anything about 60 days MADDSTACKER 07/19/17 04:37:10 PM
#451   Fast track. 60 day trial. Started jimbob4stocks 07/19/17 04:35:29 PM
#450   What trial are they in ? MADDSTACKER 07/19/17 04:33:06 PM
#449   Waiting on FDA news. 5 years of jimbob4stocks 07/19/17 04:29:05 PM
#448   Added some more ready for some updates and MADDSTACKER 07/19/17 04:25:48 PM
#447   Added another 20K @ .0835 jimbob4stocks 07/17/17 02:26:45 PM
#446   Agreed easily ..:) MADDSTACKER 07/17/17 10:01:43 AM
#445   Keep giving me cheapies! When this hits jimbob4stocks 07/14/17 03:29:41 PM
#444   BARDA's decision was heavily because of AOLS not jimbob4stocks 07/12/17 08:34:11 AM
#443   Awesome , I'm holding thank you !! MADDSTACKER 07/11/17 12:37:03 PM
#442   FDA fast track takes 60 days or less. jimbob4stocks 07/11/17 12:35:28 PM
#441   Hi , not sure why we aren't way MADDSTACKER 07/11/17 12:29:52 PM
#440   Accumulating jimbob4stocks 07/10/17 10:09:06 AM
#439   Aeolus Pharmaceutica (AOLS) mick 07/09/17 10:05:19 AM
#438   Goal is 60 days. Should hear back jimbob4stocks 07/07/17 11:00:37 AM
#437   Anyone here ask few ? MADDSTACKER 06/14/17 10:47:44 AM
#436   Crazy ...this should went way higher ... MADDSTACKER 06/09/17 12:00:10 PM
#435   Was out of pocket all day. I am Sheep 06/08/17 07:40:55 PM
#434   This test is being funded by us government MADDSTACKER 06/08/17 03:05:08 PM
#433   Looks like dilutor so are gone !! MADDSTACKER 06/08/17 01:32:26 PM
#432   I'm also holding long for the gap fill LtRyan 06/08/17 12:19:56 PM
#431   Should work its way back up IMHO look MADDSTACKER 06/08/17 11:44:18 AM
#430   Well...that was anticlimactic! LtRyan 06/08/17 11:08:06 AM
#429   Says only product in market like this .... MADDSTACKER 06/08/17 10:47:19 AM
#428   FDA fast track news: FDA fast track designation LtRyan 06/08/17 10:46:10 AM
#427   Fast track !!!!! MADDSTACKER 06/08/17 10:45:37 AM
#426   Wow someone stepping out the last few days. Sheep 05/31/17 09:47:41 AM
#425   Now this is positive news: Sheep 05/16/17 09:52:20 AM
#424   AOLS News: Current Report Filing (8-k) 03/24/2017 11:51:26 AM mick 05/14/17 11:47:32 AM
#423   Aeolus Pharmaceutica (AOLS) mick 05/14/17 11:47:26 AM
#422   CSTI just sucks up sells on the bid. jimbob4stocks 05/08/17 03:11:35 PM
#421   I wondered the same thing. I wonder if Sheep 04/28/17 04:23:20 PM
#420   Big move coming Monday! jimbob4stocks 04/28/17 04:22:16 PM
#419   Nice hit at the ask. Now we just Sheep 04/28/17 03:52:49 PM
#418   Great article! This reminds me of those jimbob4stocks 04/12/17 08:53:52 AM
#417   Wow that is coming directly from Dr. Rick Sheep 04/11/17 04:01:51 PM
#416   Aols is mentioned in this Bloomberg article today: SF Wolf 04/11/17 09:25:53 AM
#415   Aeolus Pharmaceutica (AOLS) mick 04/08/17 12:02:08 PM
#414   Morning $AOLS Rogue Dead Guy 04/05/17 06:23:45 AM
#413   http://ir.aolsrx.com/ All the investor stuff you need jimbob4stocks 04/04/17 01:13:53 PM
#412   I emailed the company to see if they Sheep 04/04/17 09:50:34 AM
PostSubject